Formulation and Evaluation of Cisplatin Niosomal Drug Delivery System
Abstract
The present study was focused on formulating and evaluating Cisplatin containing niosomes formulation for invitro studies. Niosomal formulations were prepared by using different ratio of surfactant (Tween 80 and Span 80) and cholesterol by thin film hydration method and were evaluated for in vitro characteristics, stability studies. Span 80 containing niosomal formulation displayed highest entrapment efficiency with desired particle size. SEM analyses showed that niosomal formulation was spherical in shape. Niosomes containing Span 80 displayed higher percentage of drug release after 8h as compared to other formulations. F-4 formulation was found to be stable at the end of the study on storage condition. The present study suggested that niosomal formulations provide sustained and prolonged delivery of drug with enhance bioavailability.
How to Cite This Article
Dr. P Sobitha Rani, Afifa Nazeen, B Laharika, K Mohan varma, K Naresh, Mohd Sameer (2026). Formulation and Evaluation of Cisplatin Niosomal Drug Delivery System . International Journal of Multidisciplinary Research and Growth Evaluation (IJMRGE), 7(3), 704-709.
References
- 1. Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A. The preparation and properties of niosomes—non-ionic surfactant vesicles. J Pharm Pharmacol. 1985;37:863–868.
- 2. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm. 1998;172:33–70.
- 3. Moghassemi S, Hadjizadeh A. Nano-niosomes as nanoscale drug delivery systems: An illustrated review. J Control Release. 2014;185:22–36.
- 4. Kaur IP, Mehta R. Niosomes as a potential carrier system for drug delivery: A review. Asian J Pharm Sci. 2017;12:1–15.
- 5. Torchilin VP. Micellar nanocarriers: Pharmaceutical perspectives. Pharm Res. 2007;24:1–16.
- 6. Gonzalez-Ramos J, et al. Cisplatin: mode of action, toxicity and resistance mechanisms. Oncol Rev. 2011;5:1–12.
- 7. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378.
- 8. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics. J Control Release. 2000;65:271–284.
- 9. Patel J, Patel B, Banwait H, Parmar K, Patel M. Formulation and evaluation of topical niosomal gel of erythromycin. Int J PharmTech Res. 2010;2:192–201.
- 10. Khan R, Irchhaiya R, Sharma A. Niosomes: A potential tool for novel drug delivery. J Drug Deliv Ther. 2016;6:1–10.
- 11. Chaudhari PD, Desai US. Formulation and evaluation of niosomal in situ gel of prednisolone sodium phosphate for ocular drug delivery. Int J Appl Pharm. 2019;11(2):97–116.
- 12. Sambhakar S, Singh B, Paliwal SK, Mishra PR. Niosomes as a potential carrier for controlled release of cefuroxime axetil. Asian J Biochem Pharm Res. 2011;1(1):3.
- 13. Sakthivel M, Kannan K, Manavalan R, Senthamarai R. Formulation and in vitro evaluation of niosomes containing oxcarbazepine. Int J Pharm Pharm Sci. 2012;4(3).
- 14. Srivastav A, Das P. To study the formulation of niosome of ofloxacin and its evaluation for efficacy of antimicrobial. Int J Innov Res Sci Eng Technol. 2014;3:17958–17965.
- 15. Mishra N, Srivastava V, Kaushik A, Chauhan V, Srivastava G. Formulation and in vitro evaluation of niosomes of aceclofenac. J Sci Ind Res. 2014;73:337– 341.